DK3097925T3 - Farmaceutisk sammensætning - Google Patents

Farmaceutisk sammensætning Download PDF

Info

Publication number
DK3097925T3
DK3097925T3 DK16179161.1T DK16179161T DK3097925T3 DK 3097925 T3 DK3097925 T3 DK 3097925T3 DK 16179161 T DK16179161 T DK 16179161T DK 3097925 T3 DK3097925 T3 DK 3097925T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
DK16179161.1T
Other languages
English (en)
Inventor
Andrea Pfeifer
Andreas Muhs
Leuven Fred Van
Bosch Maria Pihlgren
Original Assignee
Ac Immune Sa
Katholieke Univ Leuven Ku Leuven Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3097925(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa, Katholieke Univ Leuven Ku Leuven Research & Development filed Critical Ac Immune Sa
Application granted granted Critical
Publication of DK3097925T3 publication Critical patent/DK3097925T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DK16179161.1T 2009-04-03 2010-04-01 Farmaceutisk sammensætning DK3097925T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157303 2009-04-03
EP10713172.4A EP2413957B1 (en) 2009-04-03 2010-04-01 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
DK3097925T3 true DK3097925T3 (da) 2019-08-05

Family

ID=42269736

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10713172.4T DK2413957T3 (da) 2009-04-03 2010-04-01 Farmaceutisk sammensætning
DK16179161.1T DK3097925T3 (da) 2009-04-03 2010-04-01 Farmaceutisk sammensætning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10713172.4T DK2413957T3 (da) 2009-04-03 2010-04-01 Farmaceutisk sammensætning

Country Status (29)

Country Link
US (3) US8647631B2 (da)
EP (2) EP2413957B1 (da)
JP (2) JP5810076B2 (da)
KR (2) KR101770436B1 (da)
CN (2) CN102946899B (da)
AU (1) AU2010233856B2 (da)
BR (1) BRPI1015088B1 (da)
CA (1) CA2757345C (da)
CL (2) CL2011002457A1 (da)
CO (1) CO6390113A2 (da)
CR (1) CR20110509A (da)
DK (2) DK2413957T3 (da)
EC (1) ECSP11011367A (da)
ES (2) ES2595371T3 (da)
HK (2) HK1164127A1 (da)
HU (2) HUE044981T2 (da)
IL (1) IL215451A (da)
MA (1) MA34120B1 (da)
MX (1) MX2011010353A (da)
MY (1) MY171300A (da)
NZ (1) NZ595856A (da)
PL (2) PL2413957T3 (da)
PT (2) PT2413957T (da)
RU (1) RU2582916C2 (da)
SG (1) SG175037A1 (da)
SI (2) SI2413957T1 (da)
UA (1) UA107571C2 (da)
WO (1) WO2010115843A2 (da)
ZA (1) ZA201107776B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US9605054B2 (en) * 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
CA2755683A1 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2012020124A1 (en) * 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
TW201216985A (en) * 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
TW201223561A (en) 2010-10-26 2012-06-16 Ac Immune Sa Preparation of an antigenic construct
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SG10201912964PA (en) * 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
EP2764022B9 (en) 2011-10-07 2017-02-22 AC Immune S.A. Phosphospecific antibodies recognising tau
MX356800B (es) * 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
DK2857039T3 (da) * 2012-05-31 2019-12-16 Univ Osaka City Terapeutisk middel eller profylaktisk middel mod demens
CN104781278B (zh) 2012-07-03 2018-06-12 华盛顿大学 针对tau的抗体
MX359817B (es) 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX2015012872A (es) * 2013-03-15 2016-02-03 Ac Immune Sa Anticuerpos anti-tau y metodos de uso.
PL3083680T3 (pl) 2013-12-20 2020-06-29 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
EP3313877B1 (en) 2015-06-24 2020-06-03 H. Hoffnabb-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
MA41669A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
IL266862B2 (en) 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and preparations for their administration
AU2017373884A1 (en) 2016-12-07 2019-05-30 Ac Immune Sa Anti-tau antibodies and methods of their use
CR20230163A (es) 2016-12-07 2023-07-06 Genentech Inc ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
AU2018355325A1 (en) * 2017-10-25 2020-05-07 Ac Immune S.A. Compositions of phosphorylated tau peptides and uses thereof
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
CN113710269A (zh) 2019-02-08 2021-11-26 Ac免疫有限公司 磷酸化Tau肽疫苗的安全施用方法
JP2022529529A (ja) 2019-04-24 2022-06-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド タウワクチンの異種投与
AR122721A1 (es) 2020-06-25 2022-09-28 Merck Sharp & Dohme Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
WO2022144406A1 (en) * 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US5843779A (en) * 1992-12-14 1998-12-01 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
DE69830192T2 (de) * 1997-12-03 2006-01-12 Biogen Idec Ma Inc., Cambridge Hydrophobisch-modifizierte Hedgehog Protein Zusammensetzungen und Verfahren
WO2002004949A2 (en) 2000-07-11 2002-01-17 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
JP2006525226A (ja) 2002-12-24 2006-11-09 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
AU2006326283B2 (en) * 2005-12-12 2012-01-19 Ac Immune S.A. Therapeutic vaccine
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
CA2702880A1 (en) 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to a beta oligomer, and use thereof
CA2755683A1 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
SG177637A1 (en) 2009-07-30 2012-03-29 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof

Also Published As

Publication number Publication date
EP2413957A2 (en) 2012-02-08
US20140255412A1 (en) 2014-09-11
EP3097925A1 (en) 2016-11-30
KR20120034609A (ko) 2012-04-12
PT2413957T (pt) 2016-09-30
US8647631B2 (en) 2014-02-11
JP2015214559A (ja) 2015-12-03
MX2011010353A (es) 2011-12-06
CL2013002888A1 (es) 2014-09-05
HK1231408A1 (zh) 2017-12-22
ECSP11011367A (es) 2012-03-30
NZ595856A (en) 2014-05-30
DK2413957T3 (da) 2016-10-10
BRPI1015088B1 (pt) 2021-06-29
KR20150041203A (ko) 2015-04-15
WO2010115843A3 (en) 2010-12-02
IL215451A0 (en) 2011-12-29
CL2011002457A1 (es) 2012-03-16
US20120183599A1 (en) 2012-07-19
JP5810076B2 (ja) 2015-11-11
CN105524160B (zh) 2019-07-19
SI2413957T1 (sl) 2016-12-30
KR101770436B1 (ko) 2017-08-23
CA2757345A1 (en) 2010-10-14
SI3097925T1 (sl) 2019-11-29
EP3097925B1 (en) 2019-06-12
PT3097925T (pt) 2019-07-23
RU2011144307A (ru) 2013-05-10
ES2738623T3 (es) 2020-01-24
AU2010233856B2 (en) 2014-04-10
BRPI1015088A2 (pt) 2016-06-28
CN102946899A (zh) 2013-02-27
RU2582916C2 (ru) 2016-04-27
MA34120B1 (fr) 2013-04-03
PL3097925T3 (pl) 2020-02-28
IL215451A (en) 2016-05-31
HK1164127A1 (zh) 2012-09-21
ZA201107776B (en) 2014-03-26
AU2010233856A1 (en) 2011-10-27
JP2012522754A (ja) 2012-09-27
EP2413957B1 (en) 2016-07-27
CR20110509A (es) 2012-02-09
CO6390113A2 (es) 2012-02-29
PL2413957T3 (pl) 2017-01-31
SG175037A1 (en) 2011-11-28
MY171300A (en) 2019-10-07
CA2757345C (en) 2020-04-14
WO2010115843A2 (en) 2010-10-14
UA107571C2 (xx) 2015-01-26
ES2595371T3 (es) 2016-12-29
AU2010233856A2 (en) 2011-10-27
US20150259406A1 (en) 2015-09-17
CN102946899B (zh) 2016-01-20
HUE030428T2 (en) 2017-05-29
CN105524160A (zh) 2016-04-27
HUE044981T2 (hu) 2019-12-30

Similar Documents

Publication Publication Date Title
SMT201700095B (is) Composizioni farmaceutiche per inalazione
SMT201700008B (it) Composizione farmaceutica
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
SMT201600350B (it) Composizioni farmaceutiche
SMT201600307B (it) Composizione liposomiale
BRPI1015939A2 (pt) composição farmacêutica
BRPI1012539A2 (pt) composições farmacêuticas
DK3246018T3 (da) Farmaceutisk sammensætning
BRPI1013588A2 (pt) composição
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BRPI0920521A2 (pt) combinação farmacêutica
SMT201400069B (it) Formulazione farmaceutica
DK2395834T3 (da) Natriumnitrit-holdige farmaceutiske sammensætninger
BRPI1015474A2 (pt) composição
IT1394400B1 (it) Composizioni farmaceutiche
EE201300005A (et) Ravimkoostis
DK2285413T3 (da) Farmaceutisk sammensætning
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0922653A2 (pt) preparação farmacêutica
CO6801722A2 (es) Composiciones farmacéuticas
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas